Sökning: "Kristina Drott"

Hittade 3 avhandlingar innehållade orden Kristina Drott.

  1. 1. How can p53 induce differentiation of leukemic cells?

    Författare :Kristina Drott; Avdelningen för hematologi och transfusionsmedicin; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; extracellular fluids; p53-differentiation-p21-WT1-leukemia; Hematologi; Haematology; extracellulära vätskor;

    Sammanfattning : The terminal differentiation of leukemic cells is closely connected to their death. The concept of differentiation therapy originates from the idea that forced maturation of leukemic cells could induce cell death without the side-effects that are provoked by ordinary chemotherapy. LÄS MER

  3. 2. Targeted Inhibition of Polycomb Repressive Complexes in Multiple Myeloma : Implications for Biology and Therapy

    Författare :Mohammad Alzrigat; Helena Jernberg-Wiklund; Fredrik Öberg; Kristina Drott; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Multiple Myeloma; Epigenetics; Polycomb; PRC2; PRC1; EZH2; BMI-1; UNC1999; PTC-209; Epigenetic Therapy; Medicinsk vetenskap; Medical Science; Molekylär medicin; Molecular Medicine;

    Sammanfattning : Multiple myeloma (MM) is a hematological malignancy of antibody producing plasmablasts/plasma cells. MM is characterized by extensive genetic and clonal heterogeneity, which have hampered the attempts to identify a common underlying mechanism for disease establishment and development of appropriate treatment regimes. LÄS MER

  4. 3. Clinical and tumour biology studies of Diffuse Large B-cell Lymphoma : with emphasis on comorbidity, toxicity and outcome

    Författare :Charlott Mörth; Gunilla Enblad; Kristina Drott; Uppsala universitet; []
    Nyckelord :DLBCL; autoimmune disease; cardiac toxicity; neurotoxicity; EFS; OS; Medicinsk vetenskap; Medical Science;

    Sammanfattning : Diffuse large B-cell lymphoma (DLBCL) is curable in around 70% when treated with standard immunochemotherapy R- CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). Treatment related toxicity affecting survivors is a clinical problem as well as comorbidities influencing the possibility to give adequate treatment. LÄS MER